StreetInsider.com News Articles

ME Therapeutics Extends Option Agreement for CD22 Nanobody Asset

Fri, 09 Oct 2026 18:35:00 -0400

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer-fighting drugs in the field of immuno-oncology, today announced an extension to its option agreement to license the National Research Council of Canada’s (NRC) proprietary nanobody-based CD22 binder for use in Chimeric Antigen Receptor (CAR) therapy. ME Therapeutics will continue developing the CD22 nanobody as part of its in vivo CAR program. The option to license the CD22 binder is now exercisable until February 10, 2027. All other terms remain the same.

About

ME Therapeutics Extends Option Agreement for CD22 Nanobody Asset

Fri, 09 Oct 2026 18:35:00 -0400

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer-fighting drugs in the field of immuno-oncology, today announced an extension to its option agreement to license the National Research Council of Canada’s (NRC) proprietary nanobody-based CD22 binder for use in Chimeric Antigen Receptor (CAR) therapy. ME Therapeutics will continue developing the CD22 nanobody as part of its in vivo CAR program. The option to license the CD22 binder is now exercisable until February 10, 2027. All other terms remain the same.
About

ME Therapeutics Advances In Vivo CAR and Therapeutic mRNA STING Programs

Tue, 08 Sep 2026 09:00:00 -0400

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to provide a comprehensive update on its in vivo CD19/CD22-targeted chimeric antigen receptor (CAR) program, therapeutic mRNA STING program, and ongoing corporate initiatives.
In Vivo CAR Program
ME Therapeutics has successfully advanced its in vivo CAR pipeline to yield two differentiated lead constructs, each engineered with a distinct approach to targeting both CD19 and CD22 to treat certain blood cancers and

ME Therapeutics Advances In Vivo CAR and Therapeutic mRNA STING Programs

Tue, 08 Sep 2026 09:00:00 -0400

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to provide a comprehensive update on its in vivo CD19/CD22-targeted chimeric antigen receptor (CAR) program, therapeutic mRNA STING program, and ongoing corporate initiatives.
In Vivo CAR Program
ME Therapeutics has successfully advanced its in vivo CAR pipeline to yield two differentiated lead constructs, each engineered with a distinct approach to targeting both CD19 and CD22 to treat certain blood cancers and

ME Therapeutics closes $576,500 private placement on CSE

Fri, 17 Jul 2026 09:00:30 -0400

ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T), a Vancouver-based biotechnology company, has closed a non-brokered private placement raising $576,500.60.

The financing consisted of 339,118 units priced at $1.70 per unit. Each unit includes one common share and one non-transferable warrant exercisable at $2.00 per share for three years. An acceleration clause allows the company to shorten the warrant expiry with 30 days' notice if the volume-weighted average share price reaches $3.00 for ten consecutive trading days. All shares and warrants are subject to a hold period of four months and one day from issuance.

The company said proceeds will be directed

ME Therapeutics closes $576,500 private placement on CSE

Fri, 17 Jul 2026 09:00:30 -0400

ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T), a Vancouver-based biotechnology company, has closed a non-brokered private placement raising $576,500.60.

The financing consisted of 339,118 units priced at $1.70 per unit. Each unit includes one common share and one non-transferable warrant exercisable at $2.00 per share for three years. An acceleration clause allows the company to shorten the warrant expiry with 30 days' notice if the volume-weighted average share price reaches $3.00 for ten consecutive trading days. All shares and warrants are subject to a hold period of four months and one day from issuance.

The company said proceeds will be directed

ME Therapeutics closes $576,500 private placement on CSE

Fri, 17 Jul 2026 09:00:30 -0400

ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T), a Vancouver-based biotechnology company, has closed a non-brokered private placement raising $576,500.60.

The financing consisted of 339,118 units priced at $1.70 per unit. Each unit includes one common share and one non-transferable warrant exercisable at $2.00 per share for three years. An acceleration clause allows the company to shorten the warrant expiry with 30 days' notice if the volume-weighted average share price reaches $3.00 for ten consecutive trading days. All shares and warrants are subject to a hold period of four months and one day from issuance.

The company said proceeds will be directed

ME Therapeutics Closes Over-Subscribed Private Placement

Fri, 17 Jul 2026 09:00:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has closed its previously announced non-brokered private placement for aggregate proceeds of $576,500.60 (the “Financing”).
Closing of the Financing
The Financing consisted of the issuance of 339,118 units of the Company (each a “Unit”) at a price of $1.70 per Unit, with

ME Therapeutics Closes Over-Subscribed Private Placement

Fri, 17 Jul 2026 09:00:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has closed its previously announced non-brokered private placement for aggregate proceeds of $576,500.60 (the “Financing”).
Closing of the Financing
The Financing consisted of the issuance of 339,118 units of the Company (each a “Unit”) at a price of $1.70 per Unit, with

ME Therapeutics Closes Over-Subscribed Private Placement

Fri, 17 Jul 2026 09:00:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has closed its previously announced non-brokered private placement for aggregate proceeds of $576,500.60 (the “Financing”).
Closing of the Financing
The Financing consisted of the issuance of 339,118 units of the Company (each a “Unit”) at a price of $1.70 per Unit, with

ME Therapeutics Closes Over-Subscribed Private Placement

Fri, 17 Jul 2026 09:00:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has closed its previously announced non-brokered private placement for aggregate proceeds of $576,500.60 (the “Financing”).
Closing of the Financing
The Financing consisted of the issuance of 339,118 units of the Company (each a “Unit”) at a price of $1.70 per Unit, with

ME Therapeutics Closes Over-Subscribed Private Placement

Fri, 17 Jul 2026 09:00:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has closed its previously announced non-brokered private placement for aggregate proceeds of $576,500.60 (the “Financing”).
Closing of the Financing
The Financing consisted of the issuance of 339,118 units of the Company (each a “Unit”) at a price of $1.70 per Unit, with

ME Therapeutics Closes Over-Subscribed Private Placement

Fri, 17 Jul 2026 09:00:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has closed its previously announced non-brokered private placement for aggregate proceeds of $576,500.60 (the “Financing”).
Closing of the Financing
The Financing consisted of the issuance of 339,118 units of the Company (each a “Unit”) at a price of $1.70 per Unit, with

ME Therapeutics Closes Over-Subscribed Private Placement

Fri, 17 Jul 2026 09:00:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has closed its previously announced non-brokered private placement for aggregate proceeds of $576,500.60 (the “Financing”).
Closing of the Financing
The Financing consisted of the issuance of 339,118 units of the Company (each a “Unit”) at a price of $1.70 per Unit, with

ME Therapeutics Closes Over-Subscribed Private Placement

Fri, 17 Jul 2026 09:00:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has closed its previously announced non-brokered private placement for aggregate proceeds of $576,500.60 (the “Financing”).
Closing of the Financing
The Financing consisted of the issuance of 339,118 units of the Company (each a “Unit”) at a price of $1.70 per Unit, with

ME Therapeutics announces private placement to raise up to $500,000

Wed, 03 Jun 2026 15:13:18 -0400

ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) announced a non-brokered private placement to raise gross proceeds of up to $500,000 through the issuance of up to 294,117 units at $1.70 per unit.

Each unit consists of one common share and one non-transferrable common share purchase warrant. The warrants are exercisable into additional shares at $2.00 each for three years from issuance, subject to an acceleration clause if the volume weighted average share price reaches or exceeds $3.00 for ten consecutive trading days.

The Vancouver-based biotechnology company plans to use proceeds for advancing research and development, evaluating strategic transactions, pursuing a U.S.

ME Therapeutics announces private placement to raise up to $500,000

Wed, 03 Jun 2026 15:13:18 -0400

ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) announced a non-brokered private placement to raise gross proceeds of up to $500,000 through the issuance of up to 294,117 units at $1.70 per unit.

Each unit consists of one common share and one non-transferrable common share purchase warrant. The warrants are exercisable into additional shares at $2.00 each for three years from issuance, subject to an acceleration clause if the volume weighted average share price reaches or exceeds $3.00 for ten consecutive trading days.

The Vancouver-based biotechnology company plans to use proceeds for advancing research and development, evaluating strategic transactions, pursuing a U.S.

ME Therapeutics announces private placement to raise up to $500,000

Wed, 03 Jun 2026 15:13:18 -0400

ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) announced a non-brokered private placement to raise gross proceeds of up to $500,000 through the issuance of up to 294,117 units at $1.70 per unit.

Each unit consists of one common share and one non-transferrable common share purchase warrant. The warrants are exercisable into additional shares at $2.00 each for three years from issuance, subject to an acceleration clause if the volume weighted average share price reaches or exceeds $3.00 for ten consecutive trading days.

The Vancouver-based biotechnology company plans to use proceeds for advancing research and development, evaluating strategic transactions, pursuing a U.S.

ME Therapeutics Announces Private Placement

Wed, 03 Jun 2026 15:13:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce a non-brokered private placement to raise gross proceeds of up to $500,000 (the “Offering”) through the issuance of up to 294,117 units (each a “Unit”) at $1.70 per Unit. Each Unit will be comprised of one common share (a “Share’) and one

ME Therapeutics Announces Private Placement

Wed, 03 Jun 2026 15:13:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce a non-brokered private placement to raise gross proceeds of up to $500,000 (the “Offering”) through the issuance of up to 294,117 units (each a “Unit”) at $1.70 per Unit. Each Unit will be comprised of one common share (a “Share’) and one

ME Therapeutics Announces Private Placement

Wed, 03 Jun 2026 15:13:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce a non-brokered private placement to raise gross proceeds of up to $500,000 (the “Offering”) through the issuance of up to 294,117 units (each a “Unit”) at $1.70 per Unit. Each Unit will be comprised of one common share (a “Share’) and one

ME Therapeutics Announces Private Placement

Wed, 03 Jun 2026 15:13:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce a non-brokered private placement to raise gross proceeds of up to $500,000 (the “Offering”) through the issuance of up to 294,117 units (each a “Unit”) at $1.70 per Unit. Each Unit will be comprised of one common share (a “Share’) and one

ME Therapeutics Announces Private Placement

Wed, 03 Jun 2026 15:13:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce a non-brokered private placement to raise gross proceeds of up to $500,000 (the “Offering”) through the issuance of up to 294,117 units (each a “Unit”) at $1.70 per Unit. Each Unit will be comprised of one common share (a “Share’) and one

ME Therapeutics Announces Private Placement

Wed, 03 Jun 2026 15:13:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce a non-brokered private placement to raise gross proceeds of up to $500,000 (the “Offering”) through the issuance of up to 294,117 units (each a “Unit”) at $1.70 per Unit. Each Unit will be comprised of one common share (a “Share’) and one

ME Therapeutics Announces Private Placement

Wed, 03 Jun 2026 15:13:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce a non-brokered private placement to raise gross proceeds of up to $500,000 (the “Offering”) through the issuance of up to 294,117 units (each a “Unit”) at $1.70 per Unit. Each Unit will be comprised of one common share (a “Share’) and one